<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832596</url>
  </required_header>
  <id_info>
    <org_study_id>Plasmavolume TDamen</org_study_id>
    <nct_id>NCT02832596</nct_id>
  </id_info>
  <brief_title>Changes in Measured Plasma Volume, Glycocalyx and Atrial Natriuretic Peptide During Anaesthesia</brief_title>
  <official_title>Changes in Measured Plasma Volume, Glycocalyx and Atrial Natriuretic Peptide During Anaesthesia, a Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The arterial blood pressure is thought to affect the ratio between filtration and
      reabsorption of fluids in the circulating blood volume and thereby the plasma volume. During
      induction of anesthesia blood pressure, hemoglobin level and hematocrits decreases and the
      plasma volume increases. The aim of the study is to evaluate weather a maintained blood
      pressure with norepinephrine during anesthesia induction reduces the increase in 125
      iodine-labeled human serum albumine (125I-HSA) measured plasma volume.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      24 patients scheduled for coronary artery bypass surgery will be included and randomized to
      receive either norepinephrine in the dose needed to maintain pre-anesthesia blood pressure or
      to a control group and receive norepinephrine only if mean arterial pressure decreases below
      60 mmHg. Equal anesthesia in both groups will be monitored. No fluids will be infused.

      Changes in vascular resistance and cardiac output will be measured with thermodilution and
      changes in plasma volume will be measured with 125I-HSA.

      Endothelial cell function will be evaluated by measuring leakage of 125I-HSA and the plasma
      concentration of endothelial cell markers. Hormonal effects will be evaluated by measuring
      the plasma concentration of atrial natriuretic peptide (ANP). Shedding of glycocalyx will be
      evaluated by measuring heparan sulphate. The level of fibrinogen and platelet function will
      be evaluated by thromboelastography/multiplate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of plasma volume measured by 125I-HSA before anesthesia induction until 50 minutes after anesthesia induction.</measure>
    <time_frame>50 minutes from anesthesia induction</time_frame>
    <description>To assess if the increase in plasma volume measured by 125I-HSA can be reduced by maintaining the blood pressure with vasopressor infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in 125I-HSA leakage</measure>
    <time_frame>50 minutes from anesthesia induction</time_frame>
    <description>To assess if there is a difference in 125I-HSA leakage in between the control and intervention groups before and after anaesthesia induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANP, heparan sulphate, thrombomodulin, fibrinogen, ROTEM</measure>
    <time_frame>50 minutes from anesthesia induction</time_frame>
    <description>To assess if there is a difference in the plasma concentration of ANP, heparan sulphate, thrombomodulin, fibrinogen and ROTEM before and after anaesthesia induction in the intervention group compared to the control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintained blood pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion</description>
    <arm_group_label>Maintained blood pressure</arm_group_label>
    <other_name>Vasopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Maintained blood pressure</intervention_name>
    <description>Norepinephrine therapy to maintain preanesthesia blood pressure</description>
    <arm_group_label>Maintained blood pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective coronary artery surgery patients

        Exclusion Criteria:

          -  Age under 40 years

          -  Untreated hypertension

          -  A reduced left ventricular systolic ejection fraction of 45% or less

          -  Diabetes mellitus

          -  Former stroke and/or a known carotid artery stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Nygren, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tor Damén, MD</last_name>
    <phone>+46313427873</phone>
    <email>tor.damen@vgregion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Nygren, MD PHD</last_name>
      <phone>+46313427444</phone>
      <email>andreas.nygren@aniv.gu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Tor Damén</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Plasma Volume</keyword>
  <keyword>Vasopressor agents</keyword>
  <keyword>Coronary artery bypass</keyword>
  <keyword>Glycocalyx</keyword>
  <keyword>ANP</keyword>
  <keyword>Coagulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

